Join
Live feed
·
PRReleasevia Quantisnow
Nurix Therapeutics Inc. logo

Nurix Therapeutics Presents Positive Results from Ongoing Clinical Trial of NX-5948 in Patients with Relapsed Refractory Chronic Lymphocytic Leukemia (CLL) at the European Hematology Association Congress (EHA2024)

ByQuantisnow·Wall Street's wire, on your screen.
NRIX· Nurix Therapeutics Inc.
Health Care

This insight was delivered by - Wall Street's wire, on your screen. Quantisnow is a real-time market data and news platform for retail investors, aggregating SEC filings, FDA approvals, analyst ratings, insider trading, and press releases into a single customizable feed. Track NRIX (Nurix Therapeutics Inc.) and more on Quantisnow.